Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED) (ATTESTED)
AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Mark Dubé R President UPTru inc., MD
- Phone Number: 1 7055222263
- Email: mark.dube@upreu.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Written informed consent, obtained from the person or legally acceptable representative, before any study-related procedure is performed. Adults aged between 18 and 65 years, inclusive, at the time of signing the informed consent form.
- A documented current substance use disorder, including but not limited to alcohol, cocaine, and/or opioid.
- Female participants must be: Not women of childbearing potential (WOCBP), i.e., postmenopausal and/or surgically sterile, OR: WOCBP who agree to use a contraceptive method that is highly effective (based on the investigator's judgment) for 28 days before and after study product administration.
- Male participants must agree to use effective birth control methods and must not donate sperm until 2 weeks after study product administration.
- Must agree not to be a gamete donor from Screening until 28 days after the follow-up telephone call.
- Willing and able to comply with the study instructions and attend all scheduled study visits.
Exclusion Criteria:
Life expectancy less than 5 years.
- Women who are pregnant or are breast-feeding.
- Known cirrhosis.
- Diagnosis of Gilbert's syndrome.
- Heart failure, classified as being in New York Heart Association Class II-IV at Screening.
- Known allergy to fluorescein, Gatorade™, or any of their excipients.
- Estimated glomerular filtration rate <30 mL/min/1.73m2 using the Cockroft-Gault method at Screening.
- Hemoglobin <120 g/L at Screening.
- Diagnosis of sickle cell anemia or sickle cell trait.
- Any major episode of infection requiring hospitalization and/or treatment with intravenous antiinfective agents during the 2 months prior to Screening.
- Use of fluorescein for medical imaging (eg, angiogram, corneal staining) in the 3 days prior to the Randomization Visit. UP
- In the opinion of the investigator, any other condition that would preclude participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fluorescein
Ingestion of 100 mg of fluorescein with 250 ml Gatorade tm
|
Oral ingestion of 100 mg of fluorescein in 250 ml of Gatorade tm
Other Names:
|
|
Placebo Comparator: placebo
ingestion of 250 ml Gatorade tm without fluorescein
|
Ingestion of 250 ml of Gatorade tm without fluorescein
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detection
Time Frame: 15 minutes post ingestion
|
Presence of fluorescence
|
15 minutes post ingestion
|
|
Detection
Time Frame: 15 minutes post ingestion
|
Presence of fluorescence .30,000
using fluorometer
|
15 minutes post ingestion
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UPTRu-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.